NIH

Dear Research Advocate: I’m pleased to announce that Senator Amy Klobuchar (D-MN) will be giving remarks at our Annual Meeting on March 16 at noon at the Willard Intercontinental Hotel. We will also be hearing from newly confirmed FDA commissioner Dr. Robert Califf and ALS patient advocate Lorri Carey. I hope you’ll join us at the annual meeting as well as at the Annual Advocacy Awards Dinner that evening. See our ad in Roll Call . Senators Patty Murray (D-WA) and Elizabeth Warren (D-MA) were joined by the eight other democratic members of the Senate HELP Committee today as they introduced the National Biomedical Research Act . This bill would provide a new mandatory funding stream for NIH...
Research conducted at Louisiana institutions benefits not only those in the state but also people across the country, said Senator Bill Cassidy (R-LA) during his opening remarks at the Louisiana Research Summit held on February 16 at the University Medical Center in New Orleans. The summit, co-hosted by Research!America, assembled federal, state, university, and business leaders to discuss current challenges and opportunities for advancing research in Louisiana. At several junctures during the summit, Senator Cassidy stressed the importance of making Louisiana "easy to work with" by lowering administrative barriers and building on success to date. He also emphasized that the summit was not...
Dear Research Advocate: This week I had the pleasure of participating in a research “summit” hosted by Louisiana State University (LSU), Research!America, and our honorary host, Senator Bill Cassidy (R-LA). I moderated a powerhouse panel featuring NIH Director Francis Collins, M.D., NSF Director France Cordova, Ph.D., and FDA’s Center for Drug Evaluation and Research (CDER) Director Janet Woodcock, M.D., each of whom offered state-specific illustrations of the impact federally-funded Louisiana research has had to date, and signalled the many opportunities Louisiana has to do more. This standing-room-only, high-content gathering drew research, academic, business and philanthropic leaders...
Dear Research Advocate: As task force meetings for Vice President Biden’s “moonshot” initiative began this week, a new public opinion survey commissioned by Research!America showed that 50% of Americans favor a tax increase to fund cancer research. While this manner of funding the moonshot is not currently on the table, the survey finding underscores the high priority Americans place on curing cancer. The President told Majority Leader McConnell and Speaker Ryan that assuring resources for research, cancer in particular, is one of his five priorities for working across the aisle this year. His FY17 budget proposal -- scheduled for release next Tuesday -- will reportedly request additional...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health (NIH), recently released a new report, the Action Plan for Lupus Research to assess opportunities for increasing scientific understanding of lupus, which will ultimately lead to safer and more effective treatments and, eventually, curative strategies. The report reflects the current need and gap in lupus research for helping to improve upon a basic understanding of the disease and to identify targets for advancing lupus drug development. Lupus is an unpredictable and misunderstood autoimmune disease that ravages different parts of the body. It is difficult to diagnose...
This was an exceptional year for publicly-funded research projects. Investments in science led to a greater understanding of preventing and treating disease such as using genetic variants to identify people at risk for coronary heart disease and tailoring breast cancer treatments to avoid the need for chemotherapy. The National Institutes of Health (NIH) also supported the work of three Nobel Prize winners and clinical advances in cancer, heart disease, MS and many other conditions. The National Science Foundation (NSF) funded interdisciplinary projects including one that led to a holistic approach to strengthening the security and effectiveness of mobile medical applications . Evidence-...
Dear Research Advocate, This holiday season, Congress has delivered a most welcome package with plenty of trimmings for patients and all of us who care about the future of health. The bipartisan deal-making is complete. A final short-term spending measure, expiring Tuesday, December 22, allows the House and Senate time to review and pass a spending bill and tax package before adjourning for the year. These two major pieces of legislation represent a real win for research; the jumpstart we need to restore the NIH budget to robust annual growth and fuel a new era of medical innovation and global leadership in both public and private sectors. As federal policymakers consider how to vote on...
Dear Research Advocate, The current continuing resolution (CR) expires tomorrow. Congress has yet to reach agreement on FY16 appropriations, so they will buy more time to hammer out a funding package by passing another CR lasting til midnight Wednesday, December 16. The major sticking points at this moment are additional policy riders attached to the funding omnibus, spanning the spectrum from immigration and refugees to labor and environmental issues. As it looks right now, some research-related budgets stand to gain, while others face a less positive fate. There’s more on NIH in my interview with The Atlantic , and we continue to press for increases for CDC, FDA, AHRQ and NSF. Social,...
Over the next three weeks, Congress has an opportunity to reverse decades of declining support for a program that is vital to our nation’s public health. House and Senate appropriators will soon determine how to allocate $25 billion in additional non-defense discretionary spending for fiscal year (FY) 2016 before the continuing resolution expires on December 11. They now have the opportunity to address the damage resulting from years’ long stagnation in federally-funded research and reinvest in the National Institutes of Health (NIH) and the National Cancer Institute (NCI). Supporters of Research!America are fully aware of the decline in our federal research enterprise. The lack of...
Dear Research Advocate, "Never Settle" is the empowering guiding theme used by Janssen Pharmaceuticals to underscore the emphasis the company places on innovation to benefit patients. In my visit to their Spring House, PA, site today to participate in a worldwide town hall, I was struck by how their theme epitomizes the advocacy drive and determination of Research!America and all our partners in advocacy for research. I was glad to report to Janssen's teams that more and more members of Congress are championing research and innovation to benefit patients worldwide. Consider the comments of Chairman Roy Blunt (R-MO) about the FY16 Senate “Labor-H” appropriations draft, which reportedly...

Pages

Sidebar Quote

Luck shouldn't play a role in why I'm alive.
Laurie MacCaskill, a seven-year pancreatic cancer survivor